Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07215832 | Karyopharm Expanded Access Program for Selinexor(KEAP) | available | — | — | Karyopharm Therapeutics IncINDUSTRY | 0 | Mar 2, 2026 | clinicaltrials |
| NCT05346835 | Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma | available | — | — | Janssen Scientific Affairs, LLCINDUSTRY | 2 | Feb 13, 2026 |
| clinicaltrials |
| NCT03123029 | Expanded Access to Venetoclax | available | — | — | AbbVieINDUSTRY | 0 | Jan 30, 2026 | clinicaltrials |
| NCT04771078 | Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release | available | — | — | CelgeneINDUSTRY | 0 | Dec 12, 2025 | clinicaltrials |
| NCT03763370 | Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma | available | — | — | GlaxoSmithKlineINDUSTRY | 0 | Oct 15, 2024 | clinicaltrials |
| NCT01250808 | Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy | available | — | — | Peking UniversityOTHER | 1 | Dec 1, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Mar 2, 2026source: clinicaltrials